Ilmonen Suvi, Vaheri Antti, Asko-Seljavaara Sirpa, Carpen Olli
Department of Plastic Surgery, Helsinki University Hospital, Helsinki, Finland.
Mod Pathol. 2005 Apr;18(4):503-10. doi: 10.1038/modpathol.3800300.
Ezrin is a member of the ezrin-radixin-moesin family of proteins that link the actin-containing cytoskeleton to the plasma membrane. Ezrin is also connected to signaling molecules involved in the regulation of cell survival, proliferation and migration. Here, we examined the expression of ezrin in 95 primary cutaneous melanomas and correlated ezrin expression with conventional prognostic factors and biomarkers. From 12 patients metastatic tissue samples were also examined. In addition to ezrin staining, Mib-1 proliferation antigen, p53 and Bcl-2 were evaluated. Ezrin immunoreactivity was seen in most tumors; only 19 (20%) melanomas were negative. A total of 48 (51%) tumors had weak immunoreactivity and 28 (29%) strong immunoreactivity. The intensity of ezrin immunoreactivity was associated with tumor thickness (Breslow, P=0.0008) and with tumor invasion level (Clark, P=0.004), thicker tumors having stronger immunoreactivity. Also, there was a correlation between higher Mib-1 index in tumors and strong ezrin expression. All metastatic samples (n=12) showed positive ezrin immunoreactivity. In univariate analysis of survival, patients (n=76) with positive ezrin immunoreactivity had worse clinical disease behavior than those (n=19) without ezrin immunoreactivity, but the difference was not significant (P=0.19). In multivariate analysis of survival, the ezrin immunoreactivity was not a significant marker. The results indicate that ezrin is expressed in most primary melanomas of the skin and in all metastatic tumors. Ezrin expression correlates with tumor thickness and level of invasion suggesting an association between ezrin expression and tumor progression.
埃兹蛋白是埃兹蛋白-根蛋白-膜突蛋白家族的成员之一,该家族蛋白将含肌动蛋白的细胞骨架与质膜相连。埃兹蛋白还与参与细胞存活、增殖和迁移调节的信号分子相关。在此,我们检测了95例原发性皮肤黑色素瘤中埃兹蛋白的表达,并将埃兹蛋白表达与传统预后因素及生物标志物进行关联分析。还对12例患者的转移组织样本进行了检测。除了埃兹蛋白染色外,还评估了Mib-1增殖抗原、p53和Bcl-2。大多数肿瘤中可见埃兹蛋白免疫反应性;仅19例(20%)黑色素瘤为阴性。共有48例(51%)肿瘤免疫反应性较弱,28例(29%)免疫反应性较强。埃兹蛋白免疫反应性强度与肿瘤厚度( Breslow,P = 0.0008)及肿瘤浸润水平(Clark,P = 0.004)相关,肿瘤越厚,免疫反应性越强。此外,肿瘤中较高的Mib-1指数与埃兹蛋白强表达之间存在相关性。所有转移样本(n = 12)均显示埃兹蛋白免疫反应性阳性。在生存单因素分析中,埃兹蛋白免疫反应性阳性的患者(n = 76)临床疾病行为比无埃兹蛋白免疫反应性的患者(n = 19)差,但差异无统计学意义(P = 0.19)。在生存多因素分析中,埃兹蛋白免疫反应性不是一个显著的标志物。结果表明,埃兹蛋白在大多数原发性皮肤黑色素瘤及所有转移瘤中均有表达。埃兹蛋白表达与肿瘤厚度及浸润水平相关,提示埃兹蛋白表达与肿瘤进展之间存在关联。